Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Beta-caryophyllene (BCP) is a dietary sesquiterpene found in various plants such as black pepper, cloves, and cannabis. Its primary mechanism of action is as a selective agonist of the cannabinoid receptor type 2 (CB2), which is involved in modulating inflammation and pain. The interest in BCP for fibromyalgia syndrome (FMS) stems from its analgesic and anti-inflammatory properties demonstrated in preclinical studies. Animal models show BCP can reduce chronic pain behaviors and inflammatory responses via CB2 receptor activation, which is relevant since fibromyalgia is characterized by chronic widespread pain and often involves dysregulation of pain signaling and neuroinflammation.

However, direct evidence supporting the use of BCP in FMS patients is limited. To date, there are no published human clinical trials specifically evaluating BCP for fibromyalgia. Most of the supporting data comes from animal models of neuropathic or inflammatory pain, which may share some mechanistic overlap with FMS but are not the same condition. A small number of review articles and mechanistic studies suggest that CB2 agonists like BCP could potentially modulate pain, mood, and immune responses relevant to fibromyalgia, but these are largely speculative or extrapolated from other pain conditions.

In summary, while the pharmacological rationale for BCP in fibromyalgia is scientifically plausible and supported by preclinical research, there is currently insufficient direct clinical evidence. Thus, the scientific evidence rating is 2/5, indicating preliminary but inconclusive support.

More about beta caryophyllene
More about Fibromyalgia Syndrome

Other ingredients used for Fibromyalgia Syndrome

Other health conditions supported by beta caryophyllene

Products containing beta caryophyllene